ICH M11, the first internationally harmonized clinical trial protocol template, reached Step 4 finalization in November 2025. The FDA and EMA have both adopted it, effective mid-2026. The template standardizes where protocol content goes, splitting inclusion and exclusion criteria into separate sections (5.2 and 5.3), moving trial stopping rules to 4.3, and requiring plain-language trial titles on the cover page. For trials estimating treatment effect, the synopsis must now include estimands in layperson language. The introduction section should focus on study-specific benefit-risk rather than restating background from the Investigator's Brochure. The template itself is finalized, but structured, machine-readable exchange requires an additional layer. CDISC's USDM v4.0 and the HL7 Vulcan FHIR guide (still in ballot) are prominent ecosystem approaches, not separate M11 requirements. The FDA guidance is a recommendation, not a legal mandate. Sponsors should check their region's adoption notice directly and update authoring workflows now, before the next protocol cycle.